GPT and diabetes mellitus: Compared with individuals without MASLD, those with MASLD exhibited significantly higher BMI (mean: 27.3 vs 22.1 kg/m2), a greater burden of metabolic comorbidities (diabetes prevalence: 28.4% vs 5.9%), and elevated levels of hepatic enzymes (alanine aminotransferase: 42.1 vs 19.8 U/L).